However, it is not approved by the FDA for medical treatment
August 2025 : The US FDA approved Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity
He says losing pounds doesn't automatically mean getting healthier
Corchado-Cobos R, Garca-Sancha N, Gonzlez-Sarmiento R, Prez-Losada J, Caueto J
BPC-157: las revisiones sealan ausencia de toxicidad reportada en preclnica y ausencia de efectos adversos mayores en los pocos estudios piloto en humanos, pero sin datos de seguridad a largo plazo (PMID 34267654)
The Role of Liposomal Technology in Cellular Health When we talk about "testing," we are ultimately looking for evidence that our wellness choices are working